Routine RSU scheme administration with no new grants or material dilution. Monitor future 6-K filings for any changes to the RSU scheme or new award grants that could affect share count.
Price Chart
Executive Summary
Ascentage Pharma disclosed that its trustee purchased 200,000 existing shares on-market (0.05% of issued shares) for HK$5.6 million to satisfy RSU vesting under the 2022 RSU Scheme. This is a routine administrative share purchase for employee equity awards with no material financial impact.
Key Facts
- Trustee purchased 200,000 existing shares on October 27, 2026 for HK$5,644,472 total consideration (HK$28.22 average per share)
- Purchased shares represent approximately 0.05% of total issued shares
- Trustee now holds 3,315,000 shares under the 2022 RSU Scheme
- No new RSU grants were made; this is a routine share purchase to satisfy previously granted RSUs upon vesting
- Trustee does not exercise voting rights on shares held
Financial Impact
HK$5.6 million share purchase representing 0.05% of outstanding shares; immaterial relative to $1.4B market cap
Risk Factors
- No material risks identified; this is a standard equity compensation administration filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-113124 |
| Document: ea030994401ex99-1.htm | 0001213900-26-113124 |
| Document: 0001213900-26-113124-index-headers.html | 0001213900-26-113124 |
| Document: 0001213900-26-113124-index.html | 0001213900-26-113124 |
| Document: 0001213900-26-113124.txt | 0001213900-26-113124 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 6-K | $14.99 $14.88 | ▼ −0.70% | ▼ −0.32% | $14.88 (−0.70%) |
Oct 22, 2026 7d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.88 (−3.63%) |
Oct 21, 2026 8d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.88 (−0.27%) |
Oct 15, 2026 14d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.88 (+1.29%) |
Sep 17, 2026 6w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.88 (+3.19%) |
Aug 19, 2026 10w ago | Press Release | $17.32 $17.00 | ▼ −1.85% | ▼ −2.26% | $14.88 (−14.09%) |
Aug 5, 2026 12w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.88 (−11.72%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.88 (−11.45%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.88 (−21.23%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.88 (−19.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers